4/A: CompuGen Ltd. Insider Trading Update

Zurit Levine, SVP of Business Development at CompuGen Ltd., filed an amended Form 4 to correct the earliest transaction date to April 10, 2026, with no changes to other reported transactions.

Summary

• This filing is an amendment to a previous Form 4, correcting the 'Date of Earliest Transaction' from April 7, 2026, to April 10, 2026.
• The amendment clarifies that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.
• Zurit Levine, SVP of Business Development, acquired 1,125 ordinary shares at $0.8292 and 2,000 ordinary shares at $1.15 on April 10, 2026.
• Additionally, 3,125 ordinary shares were disposed of at a weighted average price of $2.564 on the same date.
• The filing details the vesting schedules for stock options, with one option vesting 25% on December 31, 2023, and the remainder in quarterly installments, and another option vesting 25% on September 30, 2024, with the remainder vesting quarterly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It's an administrative correction to a previous filing with no new material information about the company's performance or strategy, only clarifying transaction dates and confirming adherence to a trading plan.

Positives

• The correction of the transaction date ensures accuracy in reporting insider activity.
• The use of a Rule 10b5-1 trading plan indicates a pre-determined strategy for stock transactions, which can be viewed positively for compliance and transparency.
• Acquisition of shares at lower prices ($0.8292 and $1.15) by an executive can signal confidence in the company's future prospects.

Negatives

• The disposal of 3,125 ordinary shares at a higher price ($2.564) by an executive might be interpreted as a profit-taking action.

Risks

• The filing does not explicitly mention any new risks or challenges.
• The vesting schedules for stock options are subject to the Reporting Person's continued service to the Issuer, implying a risk of forfeiture if service is not maintained.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. It primarily details past transactions and option vesting schedules.

Management Comments

• The filing is an amendment to correct the 'Date of Earliest Transaction' from April 7, 2026, to April 10, 2026.
• All other transaction details and holdings reported in the original filing remain unchanged.
• The transactions were made pursuant to a Rule 10b5-1 trading plan.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The correction of a date is a procedural update, and the underlying transactions, including acquisitions and disposals under a 10b5-1 plan, provide insight into executive trading activity within the biotechnology/healthcare sector.

Stakeholder Impact

• Shareholders: The clarification of transaction dates and confirmation of a 10b5-1 plan provides transparency regarding executive trading activities, which can influence investor confidence.

Next Steps

• The reporting person will continue to adhere to the Rule 10b5-1 trading plan.
• Further transactions, if any, will be reported on subsequent Form 4 filings.

Key Dates

Keywords

Form 4, Insider Trading, CompuGen Ltd., CGEN, Rule 10b5-1, Stock Options, Beneficial Ownership, Securities Exchange Act, Zurit Levine, Business Development